Abstract: A control system for cell therapy and a control method therefor. The control system may comprise a cell processing module, an auxiliary connection module, and a cell culture module which are connected in sequence; and a processor which is in communication connection with the cell processing module, the auxiliary connection module and the cell culture module, wherein the processor controls the auxiliary connection module to temporarily store a cell solution of the cell processing module and to transfer the temporarily stored cell solution to the cell culture module.

Abstract: Some embodiments of the present disclosure provide a method, a system, and a storage medium for cell sorting. The method includes: determining a count of iterations of a rough sorting operation based on a count of labeled cells in an initial cell suspension in a sample bag; obtaining an intermediate cell suspension by performing the count of iterations of rough sorting operation on the initial cell suspension, which is divided into portions according to the count of iterations; and performing at least one fine sorting operation on the intermediate cell suspension.

Abstract: A method for purifying single-stranded DNA is provided. The method can comprise: mixing a sample containing single-stranded DNA with a single-stranded DNA binding protein, and incubating for a first time period to obtain a first product, the first product containing a conjugate of the single-stranded DNA and the single-stranded DNA binding protein; purifying the first product by using affinity chromatography to obtain a second product; and purifying the second product to at least remove the single-stranded DNA binding protein to obtain a target product containing a purified single-stranded DNA. Also provided are a kit for purifying single-stranded DNA, the kit comprising a single-stranded DNA binding protein and a purification reagent; and a use of a single-stranded DNA binding protein in purifying single-stranded DNA.

Abstract: The present invention relates to a large-scale magnetic purification system, including: a liquid storage apparatus, capable of being connected to a liquid source and a waste liquid barrel through a liquid path system; a stirring system mounted above the liquid storage apparatus, where a stirring paddle of the stirring system is inserted into the liquid storage apparatus for stirring; magnets mounted around the liquid storage apparatus; a magnet actuating mechanism for manipulating the magnets to move away from or close to the liquid storage apparatus; and a control system, connected to the liquid path system, the magnet actuating mechanism, and the stirring system and controlling the liquid path system, the magnet actuating mechanism, and the stirring system.

Abstract: A primer pair, a kit and a method for detecting the residual amount of sgRNA in the environment. The forward primer of the primer pair is a nucleic acid molecule as shown in SEQ ID NO: 2, and the reverse primer of the primer pair is a nucleic acid molecule as shown in SEQ ID NO: 5. The primer pair can be used for detecting the residual amount of sgRNA in the environment; can perform real-time and high-throughput detection on the residual amount of sgRNA in the environment; has the advantages of good specificity, high sensitivity and repeatability, and convenient operation; and can perform real-time and high-throughput detection on the residual amount of the sgRNA in the environment in different stages of a production process.

Abstract: Binding molecules are provided. The binding molecules specifically bind to CD16a (Fc?RIIIA) expressed on the surface of natural killer (NK) cells, but do not bind to CD16b (Fc?RIIIB). The use of such binding molecules in the stimulation and activation of primary human NK cells is also disclosed.

Abstract: The present invention relates to a humanized anti-human PD-L1 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human PD-L1 monoclonal antibody provided in the present invention has high affinity and specificity for PD-L1, stimulates T cells to secrete cytokines, and specifically relieves the negative immune regulation by PD-L1. The effect of this antibody is not achieved by directly blocking the interaction between PD-1 and PD-L1, presenting a new mechanism of immune checkpoint regulation. Therefore, the functional humanized anti-human PD-L1 monoclonal antibody provided in the present invention activates T cells by regulating the PD-L1 signaling pathway, thereby achieving the purpose of tumor immunotherapy.

Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.

Abstract: A sample processing apparatus (100) and a use method therefor. The sample processing apparatus (100) comprises a uniform mixing mechanism (130) and a magnetic attraction mechanism (140). The sample processing apparatus (100) further comprises at least one of a sample tube (110) and a reaction tube (120). The uniform mixing mechanism (130) is configured to perform uniform mixing processing on a biological sample in the sample tube (110) and/or a biological sample in the reaction tube (120). The magnetic attraction mechanism (140) comprises a magnet (141). The magnet (141) can move relative to the sample tube (110) and/or the reaction tube (120), so as to perform magnetic attraction processing on the biological sample in the sample tube (110) and/or the biological sample in the reaction tube (120).

Abstract: The present invention provides a precursor plasmid for preparing a plasmid without selectable markers, including: 1) a replication original site; 2) a selectable marker gene; 3) a target gene or a cloning site for inserting the target gene; and 4) paired recombination sites. The paired recombination sites enable the precursor plasmid to perform self-recombination in the presence of recombinase to form a molecule of daughter plasmid and a molecule of circular double-stranded DNA. The daughter plasmid includes the replication original site and the cloning site or target gene. The circular double-stranded DNA includes the selectable marker gene. The present invention also provides a method for preparing a plasmid without selectable markers by using the precursor plasmid. The prepared plasmid without selectable markers can be used in the field of gene and cell therapy as a DNA delivery vector or a virus packaging plasmid vector to improve the safety of the plasmid.

Abstract: The present application provides an antibody fusion protein comprising: i) a multivalent (e.g., bivalent) antibody or antigen-binding fragment thereof specifically recognizing Angiopoietin-2 (Ang2)(“multivalent anti-Ang2 antibody or antigen-binding fragment thereof”), and ii) a vascular endothelial growth factor receptor (VEGFR) component, wherein the multivalent anti-Ang2 antibody or antigen-binding fragment thereof does not inhibit the binding between Ang2 and TEK receptor tyrosine kinase (TIE2). Also provided are methods of making and uses thereof.

Abstract: Provided is a dual recombinant viral vector system for expressing, in a cell, a polypeptide molecule which is composed of two different peptide chains and has an antigen binding activity, wherein the first chain is expressed using a first viral vector, the second chain is expressed using a second viral vector, and the first and second chains can be assembled, after being expressed in a cell, into the polypeptide molecule which has an antigen binding activity. Further provided are a dual plasmid system for the production of the dual recombinant viral vector system, a host cell containing the dual recombinant viral vector system, a pharmaceutical composition, and the use of and the method for delivering the polypeptide molecule to a subject by using the dual recombinant viral vector system.

Abstract: Provided is a fusion protein dimer using an antibody Fc region as the backbone, comprising a first and a second polypeptide chain. The first polypeptide chain comprises a first antibody Fc region and one or more single-domain antibodies fused to the first antibody Fc region. The second polypeptide chain comprises a second antibody Fc region and one or more single domain antibodies fused to the second antibody Fc region. The first polypeptide chain and/or the second polypeptide chain further comprise a cytokine fused to the Fc region of the respective antibody. Further provided is use of the fusion protein dimer in preparing an immunotherapeutic drug for treating tumors. The Fc fusion protein heterodimer not only increases the activity of a single domain antibody, but also significantly improves the biological activity of a cytokine.

Abstract: A sample processing apparatus (100) and a use method therefor. The sample processing apparatus (100) comprises a uniform mixing mechanism (130) and a magnetic attraction mechanism (140). The sample processing apparatus (100) further comprises at least one of a sample tube (110) and a reaction tube (120). The uniform mixing mechanism (130) is configured to perform uniform mixing processing on a biological sample in the sample tube (110) and/or a biological sample in the reaction tube (120). The magnetic attraction mechanism (140) comprises a magnet (141). The magnet (141) can move relative to the sample tube (110) and/or the reaction tube (120), so as to perform magnetic attraction processing on the biological sample in the sample tube (110) and/or the biological sample in the reaction tube (120).

Abstract: An automatic extraction device and a use method therefor. The automatic extraction device comprises a sample processing apparatus (100), a portal frame (200), a consumable assembly (300), and a pipetting apparatus (400). The sample processing apparatus (100) comprises a uniform mixing mechanism (130) and a magnetic attraction mechanism (140), which are respectively used for performing uniform mixing processing and magnetic attraction processing on a biological sample. The portal frame (200) comprises a base (201) and a moving beam (202) capable of moving relative to the base (201). The sample processing apparatus (100) and the consumable assembly (300) are provided on the base (201). The pipetting apparatus (400) is provided on the moving beam (202) for implementing a pipetting operation between the consumable assembly (300) and the sample processing apparatus (100).

Abstract: A capillary clip, a capillary electrophoresis apparatus, and a method for using a capillary clip. The capillary clip comprises a clip body, and a refrigerant channel, and at least two capillary channels defined by the clip body. The clip body comprises an inlet segment clip portion (100), a detection portion (200), and an outlet combination portion (300), wherein the inlet segment clip portion (100), the detection portion (200) and the outlet combination portion (300) are detachably connected in sequence in a sealed manner. The refrigerant channel and each capillary channel are combined at the inlet segment clip portion (100) and the outlet combination portion (300), and the refrigerant channel and each capillary channel are separated at a detection window (201) of the detection portion (200). A capillary (700) can be mounted in the capillary channel.

Abstract: An optical element detachable capillary clip and a capillary electrophoresis apparatus. The capillary clip comprises at least one capillary channel and a clip body defining the at least one capillary channel, and a capillary (700) can be mounted in the capillary channel. The clip body is provided with a detection window (201) and at least one optical detection element, the at least one optical detection element being directly or indirectly connected in the detection window (201). The at least one optical detection element can be removed from the clip body, such that the detection window (201) exposes at least part of an unobstructed region.

Abstract: An isolated antibody, or an antigen-binding portion thereof, targeting Claudin 18.2. The antibody can be single domain antibody, or its monomeric variable domain can be fused with a heavy chain constant region, such as a human IgG1 Fc. Pharmaceutical compositions including the antibody, and methods of use of the pharmaceutical compositions in the treatment of diseases are also provided.

Abstract: A blending tube (10), comprising: a tube body (20), the tube body (20) being used for accommodating a sample; and a first stirring member (30) and a second stirring member (40), which are arranged on an inner wall (200) of the tube body (20), wherein a width-to-thickness ratio of the first stirring member (30) is greater than a width-to-thickness ratio of the second stirring member (40).

Abstract: Provided is an automated system for preparing purified plasmid DNA in commercial scale.